RX Safes Releases Preliminary Research Report on C
Post# of 225
Posted On: 01/11/2016 4:27:29 AM
RX Safes Releases Preliminary Research Report on Company
Analyst Highlights Company Products and Markets With an "Outperform" Rating
HENDERSON, NV--(Marketwired - Dec 22, 2015) - Rx Safes, Inc. (OTCQB: RXSF), the developer of patented autonomous fingerprint healthcare security products announced today that it has released the company's first commissioned research report that highlights the company's products, analyzes the specific healthcare sub-markets its products are designed for, and has an outperform rating with a 2016 targeted share price of $17.41.
The research report provides a quick but thorough summary of the company and its products, provides an industry overview of the healthcare drug abuse and diversion markets, discusses recent corporate and market activity and provides an independent investment analysis provided by an industry specific analyst.
"The company wanted to start commissioning research reports in order to confirm management's business direction as well as confirm and develop shareholder opportunity. As a company, we have worked hard to develop the right technology, put that technology into the right products, are attacking the right markets with those products, and moving pro-actively in the right direction by focusing solely on the security and authorized use of controlled substances both by consumers and within professional healthcare," commented Lorraine Yarde, CEO of Rx Safes, Inc. The company is in the process of commissioning more market specific research reports that it expects to release throughout 2016.
This research report was prepared by Robert Borowski, MSc., an independent research analyst, who has provided a number of recent research reports for NASDAQ and NYSE bioscience and pharmaceutical companies such as Ohr Pharmaceutical, Calithera BioSciences and Opko Health. The report can be reviewed athttp://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf
Analyst Highlights Company Products and Markets With an "Outperform" Rating
HENDERSON, NV--(Marketwired - Dec 22, 2015) - Rx Safes, Inc. (OTCQB: RXSF), the developer of patented autonomous fingerprint healthcare security products announced today that it has released the company's first commissioned research report that highlights the company's products, analyzes the specific healthcare sub-markets its products are designed for, and has an outperform rating with a 2016 targeted share price of $17.41.
The research report provides a quick but thorough summary of the company and its products, provides an industry overview of the healthcare drug abuse and diversion markets, discusses recent corporate and market activity and provides an independent investment analysis provided by an industry specific analyst.
"The company wanted to start commissioning research reports in order to confirm management's business direction as well as confirm and develop shareholder opportunity. As a company, we have worked hard to develop the right technology, put that technology into the right products, are attacking the right markets with those products, and moving pro-actively in the right direction by focusing solely on the security and authorized use of controlled substances both by consumers and within professional healthcare," commented Lorraine Yarde, CEO of Rx Safes, Inc. The company is in the process of commissioning more market specific research reports that it expects to release throughout 2016.
This research report was prepared by Robert Borowski, MSc., an independent research analyst, who has provided a number of recent research reports for NASDAQ and NYSE bioscience and pharmaceutical companies such as Ohr Pharmaceutical, Calithera BioSciences and Opko Health. The report can be reviewed athttp://rxdrugsafe.com/files/Rx%20Safes%20Inc%20-%20Research%20Initiation.pdf
(0)
(0)GeneSYS ID, Inc. (GNID) Stock Research Links
Scroll down for more posts ▼